<p><em>頂級醫療機構的回顧性分析突顯了人工智能解決方案在發現之前未被發現的癌症和正確定位乳腺 X 光片上可疑區域的能力</em></p>
<p>馬爾伯勒，馬薩諸塞州 --（商業資訊）-- 霍洛捷公司（Nasdaq: HOLX），一家致力於改善女性健康的領先醫療技術公司，今天宣佈了新的數據，突顯了該公司的先進人工智能驅動的乳腺 X 光解決方案如何幫助檢測更多乳腺癌。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg"/></p>
<p>霍洛捷的人工智能驅動乳腺 X 光技術</p>
<p>“在霍洛捷，我們不斷推動自己進行創新，提升技術的質量和可靠性，” 乳腺與骨骼健康解決方案總裁馬克·霍瓦斯（Mark Horvath）表示。“這項研究強調了人工智能揭示可能被隱藏的癌症的潛力，同時也為我們提供了指導未來創新發展的關鍵見解。隨着我們根據客户和提供者的反饋不斷推進這項技術，我們期待看到它在現實世界中的影響。”</p>
<p>在《美國放射學雜誌》上發表的一項新研究中，波士頓麻省總醫院的研究人員對 7500 例使用霍洛捷的 Genius AI®檢測解決方案進行的數字乳腺斷層攝影（3D 乳腺 X 光）篩查進行了回顧性分析。在 2016 年至 2019 年間進行的 7500 例檢查中，有 100 例假陰性病例，即被解讀為陰性的乳腺 X 光片，但在接下來的年份中被診斷為乳腺癌。Genius AI 檢測解決方案將大約三分之一（32%）的這些病例標記為可疑區域，準確識別出隨後被診斷為乳腺癌的位置。</p>
<p>在放射科醫生之前識別的 500 例乳腺癌病例中，Genius AI 檢測技術標記了近 90% 的病例，並正確定位了它們的位置。該人工智能技術在研究中更可能標記侵襲性導管癌和淋巴結陽性癌症，而不太可能標記侵襲性小葉癌和 I 級侵襲性癌症。</p>
<p>研究中提到的一個假陰性病例涉及一名 54 歲的女性，她的結果最初被解讀為陰性。十一個月後，她因注意到左乳腺有腫塊而返回就醫，並被診斷為 I 級侵襲性導管癌。在對初次篩查乳腺 X 光片的回顧性評估中，人工智能算法標記並正確定位了癌症所在的可疑區域。</p>
<p>“在這項研究中，人工智能不僅將該病例識別為可疑並需要進一步審查，而且還正確定位了關注區域，” 麻省總醫院布里格姆婦女醫院乳腺影像質量副主任、哈佛醫學院放射學副教授馬尼莎·巴爾（Dr. Manisha Bahl）表示。“雖然還需要進一步研究，但這些發現是有希望的，突顯了人工智能在未來重新定義乳腺癌檢測的巨大潛力。”</p>
<p><strong>研究侷限性</strong></p>
<p>本研究是在一個以白人患者為主的單一學術醫療中心進行的，使用的是霍洛捷的 Genius AI 檢測 2.0 軟件，結果可能無法推廣到其他實踐環境或其他基於人工智能的算法。此外，某些子組內的小樣本量限制了統計能力和子組分析的普遍性。該研究還未評估人工智能對患者結果的影響或其在現實臨牀工作流程中的整合。</p>
<p><strong>關於 Genius AI 檢測解決方案</strong></p>
<p>霍洛捷的 Genius AI 檢測解決方案是一種創新的乳腺 X 光篩查技術，旨在定位可能代表乳腺癌的病變。可疑區域在放射科醫生的工作站上被突出顯示，以支持智能、果斷的解讀。霍洛捷的深度學習算法通過大量多樣化的患者基礎積累數據，提供豐富的見解和智能。有關更多信息，請訪問 <strong>Genius AI 檢測技術</strong>。</p>
<p><strong>關於霍洛捷公司</strong></p>
<p>霍洛捷公司是全球女性健康領域的領導者，致力於開發創新醫療技術，有效檢測、診斷和治療健康狀況，並提高全球護理標準。要了解更多信息，請訪問 www.hologic.com，並在 LinkedIn、Facebook、X、Instagram 和 YouTube 上與我們聯繫。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿可能包含涉及風險和不確定性的前瞻性信息，包括關於霍洛捷產品使用的聲明。不能保證這些產品將實現此處描述的好處，或在個別患者身上以任何特定方式複製這些好處，因為使用產品的實際效果只能逐案確定。此外，不能保證這些產品將商業成功或達到任何預期的銷售水平。霍洛捷明確聲明不承擔任何義務或承諾，公開發布任何此類聲明的更新或修訂，以反映任何期望的變化或任何此類數據或聲明所基於的事件、條件或情況的變化。</p>
<p>霍洛捷、確定科學和 Genius AI 是霍洛捷公司及其子公司在美國和/或其他國家的商標和/或註冊商標。</p>
<p><strong>參考文獻</strong></p>
<p>1 Bahl M, Kim K, Kim H, Alkhadrawi A, Do S. 商業人工智能（AI）工具用於篩查數字乳腺斷層攝影：與基於 AI 的乳腺癌檢測相關的因素。AJR Am J Roentgenol.2025 年 12 月 3 日。doi: 10.2214/AJR.25.33792。提前在線出版。PMID: 41334895。</p>
<p>來源：霍洛捷公司</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODQ0NzhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODQ0NzhyMQ"/></p>
<p>在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20251216784478/en/</p>
<p><strong>媒體聯繫人</strong></p>
<p>Bridget Perry</p>
<p>高級總監，企業傳播部</p>
<p>(+1) 508.263.8654</p>
<p>bridget.perry@hologic.com</p>
<p><strong>投資者聯繫人</strong></p>
<p>Michael Watts</p>
<p>企業副總裁，投資者關係</p>
<p>(+1) 858.410.8514</p>
<p>michael.watts@hologic.com</p>
<p>來源：Hologic, Inc.</p>

豪洛捷

<p>霍洛捷的人工智能乳腺攝影技術在一項對 7500 例檢查的研究中標記了 32% 的最初漏診乳腺癌病例。該技術準確識別了可疑區域，突顯了其改善癌症檢測的潛力。這項在馬薩諸塞州總醫院進行的研究顯示了人工智能重新定義乳腺癌檢測的能力，儘管由於樣本量和人口特徵的限制，仍存在一些侷限性。霍洛捷繼續在女性健康技術領域進行創新</p>

<p><em>Retrospective analysis at top-tier medical facility highlights AI solution’s ability to help spot previously missed cancers and correctly localize suspicious areas on mammograms</em></p>
<div class="lb-trans"><p><em>頂級醫療機構的回顧性分析突顯了人工智能解決方案在發現之前未被發現的癌症和正確定位乳腺 X 光片上可疑區域的能力</em></p>
</div><p>MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a leading medical technology company dedicated to improving women’s health, today announced new data that highlights how the company’s advanced AI-powered mammography solution can aid in detecting more breast cancers.</p>
<div class="lb-trans"><p>馬爾伯勒，馬薩諸塞州 --（商業資訊）-- 霍洛捷公司（Nasdaq: HOLX），一家致力於改善女性健康的領先醫療技術公司，今天宣佈了新的數據，突顯了該公司的先進人工智能驅動的乳腺 X 光解決方案如何幫助檢測更多乳腺癌。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg" alt="" original-src="https://mms.businesswire.com/media/20251216784478/en/2669635/4/Untitled.jpg"/></p>
<p>Hologic’s AI-Powered Mammography Technology</p>
<div class="lb-trans"><p>霍洛捷的人工智能驅動乳腺 X 光技術</p>
</div><p>“At Hologic, we are constantly pushing ourselves to innovate and enhance the quality and reliability of our technologies,” said Mark Horvath, President of Breast and Skeletal Health Solutions. “This study underscores AI’s potential to uncover cancers that might otherwise remain hidden, while also giving us critical insights to guide the development of future innovations. As we continue to advance this technology based on customer and provider feedback, we’re excited to see its impact in real-world settings.”</p>
<div class="lb-trans"><p>“在霍洛捷，我們不斷推動自己進行創新，提升技術的質量和可靠性，” 乳腺與骨骼健康解決方案總裁馬克·霍瓦斯（Mark Horvath）表示。“這項研究強調了人工智能揭示可能被隱藏的癌症的潛力，同時也為我們提供了指導未來創新發展的關鍵見解。隨着我們根據客户和提供者的反饋不斷推進這項技術，我們期待看到它在現實世界中的影響。”</p>
</div><p>In a new study1 published in the <em>American Journal of Roentgenology</em>, researchers at Massachusetts General Hospital in Boston performed a retrospective analysis of 7,500 digital breast tomosynthesis (3D mammography) screening exams using Hologic’s Genius AI® Detection solution. Among the 7,500 exams performed between 2016 and 2019, there were 100 false-negative cases, which are mammograms read as negative but followed by a breast cancer diagnosis within the next year. The Genius AI Detection solution marked approximately one-third (32%) of these cases as including areas of suspicion, accurately identifying the location where breast cancer was subsequently diagnosed.</p>
<div class="lb-trans"><p>在《美國放射學雜誌》上發表的一項新研究中，波士頓麻省總醫院的研究人員對 7500 例使用霍洛捷的 Genius AI®檢測解決方案進行的數字乳腺斷層攝影（3D 乳腺 X 光）篩查進行了回顧性分析。在 2016 年至 2019 年間進行的 7500 例檢查中，有 100 例假陰性病例，即被解讀為陰性的乳腺 X 光片，但在接下來的年份中被診斷為乳腺癌。Genius AI 檢測解決方案將大約三分之一（32%）的這些病例標記為可疑區域，準確識別出隨後被診斷為乳腺癌的位置。</p>
</div><p>Of the 500 breast cancer cases previously identified by radiologists, the Genius AI Detection technology flagged almost 90% and correctly localized their locations. The AI technology was more likely to flag invasive ductal carcinomas and lymph node-positive cancers in the study. It was less likely to flag invasive lobular carcinomas and grade I invasive carcinomas.</p>
<div class="lb-trans"><p>在放射科醫生之前識別的 500 例乳腺癌病例中，Genius AI 檢測技術標記了近 90% 的病例，並正確定位了它們的位置。該人工智能技術在研究中更可能標記侵襲性導管癌和淋巴結陽性癌症，而不太可能標記侵襲性小葉癌和 I 級侵襲性癌症。</p>
</div><p>One instance of a false-negative case flagged by AI cited in the study involved a 54-year-old woman whose results were initially interpreted as negative. Eleven months later, she returned to her doctor after noticing a lump in her left breast and was diagnosed with grade 1 invasive ductal carcinoma. On retrospective evaluation of the initial screening mammogram, the AI algorithm marked and correctly localized the area where the cancer was located as suspicious.</p>
<div class="lb-trans"><p>研究中提到的一個假陰性病例涉及一名 54 歲的女性，她的結果最初被解讀為陰性。十一個月後，她因注意到左乳腺有腫塊而返回就醫，並被診斷為 I 級侵襲性導管癌。在對初次篩查乳腺 X 光片的回顧性評估中，人工智能算法標記並正確定位了癌症所在的可疑區域。</p>
</div><p>“In this study, not only did the AI identify the case as suspicious and warranting additional review, but it also correctly localized the region of interest,” said Dr. Manisha Bahl, MD, MPH, Associate Director of Quality for Breast Imaging at Mass General Brigham and Associate Professor of Radiology at Harvard Medical School. “While additional research is needed, these findings are promising and highlight AI’s tremendous potential to redefine breast cancer detection in the years ahead.”</p>
<div class="lb-trans"><p>“在這項研究中，人工智能不僅將該病例識別為可疑並需要進一步審查，而且還正確定位了關注區域，” 麻省總醫院布里格姆婦女醫院乳腺影像質量副主任、哈佛醫學院放射學副教授馬尼莎·巴爾（Dr. Manisha Bahl）表示。“雖然還需要進一步研究，但這些發現是有希望的，突顯了人工智能在未來重新定義乳腺癌檢測的巨大潛力。”</p>
</div><p><strong>Study Limitations</strong></p>
<div class="lb-trans"><p><strong>研究侷限性</strong></p>
</div><p>This study was performed at a single academic medical center with a predominantly Caucasian patient population and was conducted with Hologic’s Genius AI Detection 2.0 software, and the results may not be generalizable to other practice settings or to other AI-based algorithms. Additionally, the small sample sizes within certain subgroup limit the statistical power and generalizability of the subgroup analyses. The study also did not evaluate the impact of AI on patient outcomes or its integration into real-world clinical workflows.</p>
<div class="lb-trans"><p>本研究是在一個以白人患者為主的單一學術醫療中心進行的，使用的是霍洛捷的 Genius AI 檢測 2.0 軟件，結果可能無法推廣到其他實踐環境或其他基於人工智能的算法。此外，某些子組內的小樣本量限制了統計能力和子組分析的普遍性。該研究還未評估人工智能對患者結果的影響或其在現實臨牀工作流程中的整合。</p>
</div><p><strong>About Genius AI Detection Solution</strong></p>
<div class="lb-trans"><p><strong>關於 Genius AI 檢測解決方案</strong></p>
</div><p>Hologic’s Genius AI Detection solution is an innovative mammography screening technology designed to locate lesions likely to represent breast cancer. Suspicious areas are highlighted at radiologists’ workstations for concurrent reading to support smart, decisive interpretation. Hologic's deep learning algorithm is fed by the accumulation of a large, diverse patient base, providing rich insight and intelligence. For more information, please visit <strong>Genius AI Detection Technology</strong>.</p>
<div class="lb-trans"><p>霍洛捷的 Genius AI 檢測解決方案是一種創新的乳腺 X 光篩查技術，旨在定位可能代表乳腺癌的病變。可疑區域在放射科醫生的工作站上被突出顯示，以支持智能、果斷的解讀。霍洛捷的深度學習算法通過大量多樣化的患者基礎積累數據，提供豐富的見解和智能。有關更多信息，請訪問 <strong>Genius AI 檢測技術</strong>。</p>
</div><p><strong>About Hologic, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於霍洛捷公司</strong></p>
</div><p>Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.</p>
<div class="lb-trans"><p>霍洛捷公司是全球女性健康領域的領導者，致力於開發創新醫療技術，有效檢測、診斷和治療健康狀況，並提高全球護理標準。要了解更多信息，請訪問 www.hologic.com，並在 LinkedIn、Facebook、X、Instagram 和 YouTube 上與我們聯繫。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.</p>
<div class="lb-trans"><p>本新聞稿可能包含涉及風險和不確定性的前瞻性信息，包括關於霍洛捷產品使用的聲明。不能保證這些產品將實現此處描述的好處，或在個別患者身上以任何特定方式複製這些好處，因為使用產品的實際效果只能逐案確定。此外，不能保證這些產品將商業成功或達到任何預期的銷售水平。霍洛捷明確聲明不承擔任何義務或承諾，公開發布任何此類聲明的更新或修訂，以反映任何期望的變化或任何此類數據或聲明所基於的事件、條件或情況的變化。</p>
</div><p>Hologic, The Science of Sure and Genius AI are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.</p>
<div class="lb-trans"><p>霍洛捷、確定科學和 Genius AI 是霍洛捷公司及其子公司在美國和/或其他國家的商標和/或註冊商標。</p>
</div><p><strong>References</strong></p>
<div class="lb-trans"><p><strong>參考文獻</strong></p>
</div><p>1 Bahl M, Kim K, Kim H, Alkhadrawi A, Do S. Commercial Artificial Intelligence (AI) Tool for Screening Digital Breast Tomosynthesis: Factors Associated With AI-Based Breast Cancer Detection. AJR Am J Roentgenol. 2025 Dec 3. doi: 10.2214/AJR.25.33792. Epub ahead of print. PMID: 41334895.</p>
<div class="lb-trans"><p>1 Bahl M, Kim K, Kim H, Alkhadrawi A, Do S. 商業人工智能（AI）工具用於篩查數字乳腺斷層攝影：與基於 AI 的乳腺癌檢測相關的因素。AJR Am J Roentgenol.2025 年 12 月 3 日。doi: 10.2214/AJR.25.33792。提前在線出版。PMID: 41334895。</p>
</div><p>SOURCE: Hologic, Inc.</p>
<div class="lb-trans"><p>來源：霍洛捷公司</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTY3ODQ0NzhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251216784478r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251216784478/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20251216784478/en/</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫人</strong></p>
</div><p>Bridget Perry</p>
<div class="lb-trans"><p>Bridget Perry</p>
</div><p>Senior Director, Corporate Communications</p>
<div class="lb-trans"><p>高級總監，企業傳播部</p>
</div><p>(+1) 508.263.8654</p>
<div class="lb-trans"><p>(+1) 508.263.8654</p>
</div><p>bridget.perry@hologic.com</p>
<div class="lb-trans"><p>bridget.perry@hologic.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫人</strong></p>
</div><p>Michael Watts</p>
<div class="lb-trans"><p>Michael Watts</p>
</div><p>Corporate Vice President, Investor Relations</p>
<div class="lb-trans"><p>企業副總裁，投資者關係</p>
</div><p>(+1) 858.410.8514</p>
<div class="lb-trans"><p>(+1) 858.410.8514</p>
</div><p>michael.watts@hologic.com</p>
<div class="lb-trans"><p>michael.watts@hologic.com</p>
</div><p>Source: Hologic, Inc.</p>
<div class="lb-trans"><p>來源：Hologic, Inc.</p>
</div>

Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams | HOLX Stock News

豪洛捷的 AI 驅動乳腺 X 光檢查技術在一項包含 7500 次篩查的研究中，標記了三分之一最初被解釋為陰性的乳腺癌病例 | HOLX 股票新聞